HRO350 / Arctic Biosci - LARVOL DELTA

Arctic Bioscience - 12-month data confirm potential for HRO350 in mild-to-moderate psoriasis (Cision) - P2b | N=521 | HeROPA (NCT06125808) | Sponsor: Arctic Bioscience | "12-month readout of the HeROPA phase 2b clinical trial shows potential through key secondary endpoint PGA 0/1, where the per protocol population approaches significance (p = 0.07) after one year of treatment. Relevant subgroups show statistical significance (p < 0.05). Importantly, HRO350 was well tolerated throughout the study, with no safety concerns or drug-related serious adverse events reported. While the primary endpoint (PASI50 at 26 weeks) in the 52-week placebo-controlled study was not met due to an unexpectedly high placebo response, the overall data support the potential of HRO350."

P2b data • Psoriasis

Arctic Bioscience – HeROPA 1-year read-out: Top-line results expected within 2-3 weeks (Cision) - "All patients have completed 1 year of treatment and the HeROPA phase 2b clinical trial on HRO350 in mild-to-moderate psoriasis is completed. Top-line results were planned to be announced by end of Q1 2025, however cleaning of the comprehensive dataset from more than 500 patients for 1 year of treatment is taking more time than anticipated. The top-line data are currently being cleaned and quality controlled. Top-line results are expected to be published within 2-3 weeks. Analyses on all endpoints will then be presented in the full clinical study report in May this year."

P2b data • Psoriasis

Efficacy and Safety Study of HRO350 in Patients with Mild-to-moderate Psoriasis (the 'HeROPA' Study). (clinicaltrials.gov) - P2 | N=521 | Completed | Sponsor: Arctic Bioscience | Active, not recruiting ➔ Completed | Trial primary completion date: Feb 2025 ➔ Oct 2024

Trial completion • Trial primary completion date • Dermatology • Immunology • Psoriasis

Efficacy and Safety Study of HRO350 in Patients With Mild-to-moderate Psoriasis (the 'HeROPA' Study). (clinicaltrials.gov) - P2 | N=521 | Active, not recruiting | Sponsor: Arctic Bioscience | Recruiting ➔ Active, not recruiting | Phase classification: P2b ➔ P2

Enrollment closed • Phase classification • Dermatology • Immunology • Psoriasis